The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-711 (COVID-19). AR-201 (RSV infection).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. HIV Research. HCV Research.

Virus 40

Virus Treatment Science Trials 40

Drug Target Review

JULY 5, 2023

In the study presented at ASGCT, what were the specific findings regarding the synergistic killing of SKOV3 ovarian tumour cells by the iPSC-derived lymphoid and myeloid cells? What are the key advancements in nucleic-acid delivery and targeted gene insertion that Eterna and Factor Bioscience presented at the ASGCT?

Therapies 104

Therapies DNA Engineering Virus 104

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Thus, the current reality of gene therapy products presents a conundrum to FDA: If you have an efficacious one-time treatment, how long do you wait to see if the treatment stops working or stops working as well, while patients receive very real benefits in the interim?

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

AUGUST 13, 2020

A trial of the English coronavirus app is getting under way. The software will tell users to self-isolate for a fortnight if the app detects they have been close to someone else diagnosed with the virus. Part of the problem at present is that Apple and Google refuse to share the raw Bluetooth signal data involved. Image caption.

Trials 52

Trials Virus Government Production 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Drug Target Review

AUGUST 25, 2023

However, in tissues where the 3 Hs are not present, the small molecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. Also, unlike several other viruses, AdAPT-001 is deliverable systemically.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

DrugBank

MARCH 12, 2025

Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. Its individualized neoantigen-specific immunotherapy platform has demonstrated promising results in early clinical trials for melanoma and other cancers.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

OCTOBER 16, 2020

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

NOVEMBER 23, 2020

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

Fierce BioTech

JULY 17, 2023

png Listing Introduction In this presentation Mathias Kahl will refer about identified challenges, learnings and solutions during IDT AAV and LV manufacturing platform establishment. Click here to login. Listing Image IDT_ListingLogo_250x190.png On Demand Start Date Thu, 09/07/2023 - 11:00

Clinical Trials 52

Clinical Trials Virus Trials Therapies 52

The Pharma Data

JUNE 25, 2021

efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. “These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. All cases observed in the vaccine group were mild as defined by the trial protocol.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

NOVEMBER 9, 2020

Trial Also Met the Primary Endpoint in Patients With Low Levels of Eosinophils. In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, the trial met the primary endpoint with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.

Trials 52

Trials Production Clinical Trials Government 52

Creative Biolabs

JUNE 2, 2020

At present, this antibody, called S309, has entered the track of rapid development and testing in Vir Biotechnology, and clinical trials may be carried out in the next step. It can neutralize SARS-CoV-2 virus by binding to the S protein fragment near the attachment site of the host cell.

Virus 52

Virus Clinical Trials Research Treatment 52

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 is being evaluated in an ongoing Phase 3 trial in the U.K. Additional terms of the agreement were not disclosed. About NVX-CoV2373. and Australia. About Matrix-M. About Novavax.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

NOVEMBER 24, 2020

The expanded approval decision was based on data from the Phase III BLOCKSTONE study, a randomized, double-blind, controlled trial of 607 individuals ages 12 years and older who were exposed to a household member with the flu. The drug was previously only available in a tablet form but is now available in granule form for mixing in water.

Virus 52

Virus FDA Trials Production 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. 13 to 15 in Boston, will be presented in a hybrid format offering either in-person or virtual attendance. to discuss the highlights of this year’s meeting.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo. THOUSAND OAKS, Calif. ,

Trials 40

Trials Production Clinical Trials Therapies 40

The Pharma Data

OCTOBER 18, 2020

The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is added to standard of care chemotherapy (pemetrexed / cisplatin). This analysis supports the data presented in June. OSLO, Norway , Oct. 361.

Virus 40

Virus Trials 40

The Pharma Data

JANUARY 12, 2021

INCHEON, South Korea–( BUSINESS WIRE )– Celltrion Group today announced top-line results from its randomised, double-blind, and placebo controlled global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. days compared to placebo [6.6 days; 95% C.I, reported with placebo.

Clinical Trials 40

Clinical Trials Treatment Trials Virus 40

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. The SARS-CoV-2 Rapid Antigen Test is for use in point of care settings for both symptomatic and asymptomatic people.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

Alta Sciences

JULY 25, 2024

Discover some of the nonclinical requirements for moving dermal studies into Phase I clinical trials, including formulation considerations, species selection, and ideal candidates for transdermal drug delivery systems (TDDS). Watch the poster presentation. Read or listen now. Watch the webinar. the UK, or the EU. the UK, or the EU.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

The Pharma Data

SEPTEMBER 29, 2020

He also hears about a trial in the US to test whether prayer can help Covid patients in intensive care. He picked up the virus right at the start of the pandemic and had a relentless and gruelling illness followed by a lingering debilitation that has lasted over six months. This is no Mickey Mouse trial either.

Doctors 52

Doctors Trials Virus Government 52

New Drug Approvals

SEPTEMBER 6, 2024

1 , 2 It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants). Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. Nature Immunol., 11:373-384 (2010)).

RNA 62

RNA Clinical Trials Disease DNA 62

The Pharma Data

DECEMBER 28, 2020

Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 5, 2021

“This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

APRIL 26, 2022

Based on these new results, Valneva and Pfizer plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

JANUARY 22, 2021

Pending ImmunityBio’s discussions with the US Food and Drug Administration , the oral vaccine will enter Phase 1 trials as a prime and boost, and will be explored as an option to provide healthcare providers with a boost to subcutaneous vaccinations.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

JANUARY 31, 2021

Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy (“PRRT”) that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells. and foreign patents.

Small Molecule 40

Small Molecule FDA Approval Trials Therapies 40

The Pharma Data

OCTOBER 21, 2020

These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek. Participants identified as impacted by COVID-19 will continue to be followed and data collected from that group is expected to be presented at a future medical meeting. Kimberly Smith, M.D., About ViiV Healthcare.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

MARCH 1, 2022

The submission was supported by data from the Phase 2/3 CAPELLA trial, which evaluated the safety and efficacy of lenacapavir administered subcutaneously every six months in combination with an optimized antiretroviral background regimen in heavily treatment-experienced people with multi-drug resistant HIV-1 infection.

FDA 52

FDA Treatment Science Therapies 52

The Pharma Data

JANUARY 31, 2021

Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52